Access critical information for business development decisions.
Create a portfolio project with all internal assets and any external assets to compare to the competing and ever-changing external landscape. Measure internal assets against predictions of each phase of development for external assets, overall development timeline and success rates of each phase and regulatory approval.
Generate licensing and partnering projects of early-stage and/or late-stage assets, with a dynamic view of the drug pipeline and clinical development status. For late-stage assets, contrast analyst consensus forecasts.
Evaluate assets of interest using Clarivate’s Indication Prioritization Insights pipeline within Business Development Analyzer to predict the diseases most relevant to the asset. For business development professionals, evaluate multiple disease potentials for an asset to support valuation/due diligence for in-licensing or out-licensing.